Abstract
The present study was designed to investigate whether the neuroprotective effect of nimesulide was mediated by inhibiting expression of matrix metalloproteinase-9 (MMP-9) and/or matrix metalloproteinase-2 (MMP-2) in a rat model of thrombolytic reperfusion after the embolic focal cerebral ischemia (FCI). It was found that nimesulide at therapeutically relevant doses (3, 6 and 12 mg/kg) decreased neurological deficits, infarct volume, brain index and brain water content in a dose-dependent manner. Hemorrhagic transformation was reduced by 64% with treatment of 12 mg/kg nimesulide. Quantitative analysis of immunohistochemical staining of brain slices showed that the neuron number expressing MMP-9 and MMP-2 increased in the model animals treated with vehicle (p < 0.01 vs sham group), and significantly decreased in nimesulide-treated animals (p < 0.05 or p < 0.01 vs vehicle group). Our results demonstrate that nimesulide significantly reduces the degree of neuronal injury and hemorrhage transformation caused by thrombolytic reperfusion after the embolic FCI, and that inhibition of MMP-9 and MMP-2 expression contributes at least in part to the neuroprotection.
Keywords: Nimesulide, neuroprotection, embolic focal cerebral ischemia, thrombolytic reperfusion, matrix metalloproteinases, hemorrhage transformation
Current Neurovascular Research
Title: A Non-Steroidal Anti-Inflammatory Agent Provides Significant Protection During Focal Ischemic Stroke with Decreased Expression of Matrix Metalloproteinases
Volume: 4 Issue: 3
Author(s): Yan Wang, Xiu-Ling Deng, Xiang-Hua Xiao and Bing-Xiang Yuan
Affiliation:
Keywords: Nimesulide, neuroprotection, embolic focal cerebral ischemia, thrombolytic reperfusion, matrix metalloproteinases, hemorrhage transformation
Abstract: The present study was designed to investigate whether the neuroprotective effect of nimesulide was mediated by inhibiting expression of matrix metalloproteinase-9 (MMP-9) and/or matrix metalloproteinase-2 (MMP-2) in a rat model of thrombolytic reperfusion after the embolic focal cerebral ischemia (FCI). It was found that nimesulide at therapeutically relevant doses (3, 6 and 12 mg/kg) decreased neurological deficits, infarct volume, brain index and brain water content in a dose-dependent manner. Hemorrhagic transformation was reduced by 64% with treatment of 12 mg/kg nimesulide. Quantitative analysis of immunohistochemical staining of brain slices showed that the neuron number expressing MMP-9 and MMP-2 increased in the model animals treated with vehicle (p < 0.01 vs sham group), and significantly decreased in nimesulide-treated animals (p < 0.05 or p < 0.01 vs vehicle group). Our results demonstrate that nimesulide significantly reduces the degree of neuronal injury and hemorrhage transformation caused by thrombolytic reperfusion after the embolic FCI, and that inhibition of MMP-9 and MMP-2 expression contributes at least in part to the neuroprotection.
Export Options
About this article
Cite this article as:
Yan Wang , Xiu-Ling Deng , Xiang-Hua Xiao and Bing-Xiang Yuan , A Non-Steroidal Anti-Inflammatory Agent Provides Significant Protection During Focal Ischemic Stroke with Decreased Expression of Matrix Metalloproteinases, Current Neurovascular Research 2007; 4 (3) . https://dx.doi.org/10.2174/156720207781387187
DOI https://dx.doi.org/10.2174/156720207781387187 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis
Current Enzyme Inhibition Magnetic Resonance Spectroscopy Biomarkers in Term Perinatal Asphyxial Encephalopathy: From Neuropathological Correlates to Future Clinical Applications
Current Pediatric Reviews Toll-Like Receptors and Kidney Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Hydrogen Sulphide in Heart and Systemic Circulation
Inflammation & Allergy - Drug Targets (Discontinued) Expression and Function of the Leukocyte Integrins in Organ Transplant Rejection
Current Medicinal Chemistry A Novel Approach to the Old Issue of Ischemic Nephropathy
Current Vascular Pharmacology Safflor Protected Rat Cerebral Ischemia-Reperfusion Injury Through Inhibiting the Expression of NF-kB and IL-1β
Neuroscience and Biomedical Engineering (Discontinued) Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Increased Severity of Acute Cerebral Ischemic Injury Correlates with Enhanced Stem Cell Induction as well as with Predictive Behavioral Profiling
Current Neurovascular Research Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis
Current Stem Cell Research & Therapy Cell-Penetrating Peptide Technology to Deliver Chaperones and Associated Factors in Diseases and Basic Research
Current Pharmaceutical Biotechnology Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets Evolving Therapeutic Targets in Ischemic Stroke: A Concise Review
Current Drug Targets Roles of Insulin Resistance, Endothelial Dysfunction and Lifestyle Changes in the Development of Cardiovascular Disease in Diabetic Patients
Current Drug Targets Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Tissue Plasminogen Activator Prevents Restoration of Tight Junction Proteins Through Upregulation of Angiopoietin-2
Current Neurovascular Research Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery